Ethical investing leads to more winners

Published 04-SEP-2020 12:51 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Taking an ethical stance with your investment choices doesn’t condemn you to under-performance. While there’s a long-held misconception that ethical investors pay dearly for the privilege of favouring companies committed to ESG (environmental, social and governance) principles, nothing could be further from the truth. Given that assets invested according to ESG-related strategies reached $30 trillion globally in 2018, Intelligent Investor senior portfolio manager Nathan Bell reminds investors that ethical investing can no longer be dismissed as a short-lived fad.

Here in Australia, Rainmaker research reported a 76 percent annual growth in ESG products (to $1.8 billion) in the three years to 30 June 2020 – almost three times the growth experienced by the rest of Australia’s exchange traded products market.

Investors don’t need to make a binary distinction between ESG and returns. Taking account of environmental, social and governance considerations in an investment process is not only important, it can improve investment outcomes.

ESG linked to returns

There’s now irrefutable evidence of a clear link between ESG investing and more informed investment decisions, plus better risk-adjusted returns in the long run. A renowned meta-study of 2,000 academic studies, reveals a 90 percent non-negative link between the incorporation of ESG factors and corporate finance performance, while 63 percent identified a positive link.

Fast forward to 2020, and the Coronavirus and its aftershocks have put a greater spotlight on the importance of ESG issues, including income inequality, diversity and inclusion, social justice, employee welfare and climate change to name a few.

While some investors assume that ESG-investments are synonymous with sub-par returns, to date these fears have been unsubstantiated. For example, a recent study also reveals that in first quarter of 2020, over 90 percent of sustainable indices out-performed their parent benchmarks.

What sceptics can take from this data is a clear reminder that if done right, ESG investing can be immensely profitable.

Intelligent Investor has top performing Ethical Share Fund

One ethical fund to out-perform its benchmark is the Intelligent Investor Ethical Share Fund (ASX: INES). Morningstar figures show that with a total return of 7.14 percent, INES is the number one ethical fund compared to 100 similar ethical managed funds benchmarked to the ASX/200 in the 12 months to 30 June 2020.

As the fund manager of INES, the fund’s out-performance during one of the toughest markets in history, can be attributed to its heavy focus on owner/manager businesses. Focusing on owner-managed companies, where the person running the business has most of their personal wealth invested – right alongside clients’ savings – is one of the most statistically reliable ways to out-perform the market. The out-performance of technology and healthcare stocks, both at home and abroad, can be attributed to the founders’ ability to increase their competitive advantages during a downturn.

The decision by weaker rivals – worried about refinancing debt and losing customers – to pull back on critical investments and marketing during COVID, has reinforced the market positions of the better run insider-owner businesses. By offering superior service when it matters, insider-owner businesses have been instrumental in taking market share off their competitors.

Given the concentration of technology and healthcare stocks – which have performed well during COVID – within ESG portfolios, the market attention they’ve attracted in the last six months isn't surprising.

Ethical funds by nature push investors into high quality businesses, which due to their strong growth trajectory, and robust balance sheets are often economically immune from cycles. All that pays off in a crisis, which is why those stocks recover the fastest.

Filtering for better returns

Listed in June 2019, INES is an active ETF designed for investors seeking a diversified basket of Australian companies with growing sustainable profits. The 20-plus stocks held within the fund, including the top five – Frontier Digital Ventures Ltd, Audinate Group Ltd, Seek Ltd, Pinnacle Investment Management and Carsales.com Ltd – are selected due to both their discount to valuation and their low risk of interruption from mounting threats linked to ESG factors.

Much of the fund’s out-performance is due to only selecting from the ASX-300, stocks that pass the ESG filters – including a commitment to addressing environmental, social and governance challenges.

The fund generally won’t invest in companies that make most of their profits from non-ESG sources, like tobacco, gambling, alcohol and resource companies.

But what’s important to note, is that by taking up this [ESG filter] process, investors are not giving up returns.

When we applied the ESG negative screen to the 420 BUY recommendations made by Intelligent Investor since 2001, the average return from the companies that passed (the ESG screen) was 14.8 percent annualised, compared to 10.1 percent for those that didn’t.

Really good businesses aren’t resource companies, they’re the ones that can produce consistent long-term profits, control product pricing and this is why we’ve made such good returns.

Nathan Bell is Nathan Bell is Intelligent Investor senior portfolio manager.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X